Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9608)
All Articles published online
|
Publishing Process of This Article
|
Mar 21, 2015 (publication date) through Feb 18, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Kim ES, Song GA, Cho KB, Park KS, Kim KO, Jang BI, Kim EY, Jeon SW, Lee HS, Yang CH, Lee YK, Lee DW, Kim SK, Kim TO, Lee J, Kim HW, Jee SR, Park SJ, Kim HJ. Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents. World J Gastroenterol 2015; 21(11): 3308-3316 [PMID: 25805938 DOI: 10.3748/wjg.v21.i11.3308] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v21/i11/3308.htm |
| Number | Citing Articles |
| 1 |
Helena Shifrin, Odelia Mouhadeb, Nathan Gluck, Chen Varol, Marta Weinstock. Cholinergic Anti-Inflammatory Pathway Does Not Contribute to Prevention of Ulcerative Colitis by Novel Indoline Carbamates. Journal of Neuroimmune Pharmacology 2017; 12(3): 484 doi: 10.1007/s11481-017-9735-8
|
| 2 |
Dong Il Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin-Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasuo Suzuki, Kentaro Sugano, Mamoru Watanabe, Toshifumi Hibi, Amarender S. Puri, Suk-Kyun Yang. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment. Intestinal Research 2018; 16(1): 4 doi: 10.5217/ir.2018.16.1.4
|
| 3 |
Yu Zhou, Juan Du, Hong-Yan Hou, Yan-Fang Lu, Jing Yu, Li-Yan Mao, Feng Wang, Zi-Yong Sun. Application of ImmunoScore Model for the Differentiation between Active Tuberculosis and Latent Tuberculosis Infection as Well as Monitoring Anti-tuberculosis Therapy. Frontiers in Cellular and Infection Microbiology 2017; 7 doi: 10.3389/fcimb.2017.00457
|
| 4 |
Roger M. Feakins. Non-Neoplastic Pathology of the Gastrointestinal Tract. 2020; : 388 doi: 10.1017/9781316823026.024
|
| 5 |
Nina Jahnich, Peter D. Arkwright. Regional risk of tuberculosis and viral hepatitis with tumor necrosis factor-alpha inhibitor treatment: A systematic review. Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1046306
|
| 6 |
Hanif Esmail, Robert J. Wilkinson. Minimizing Tuberculosis Risk in Patients Receiving Anti-TNF Therapy. Annals of the American Thoracic Society 2017; 14(5): 621 doi: 10.1513/AnnalsATS.201701-055ED
|
| 7 |
Ibrahim Abubakar, Ajit Lalvani, Jo Southern, Alice Sitch, Charlotte Jackson, Oluchukwu Onyimadu, Marc Lipman, Jonathan J Deeks, Chris Griffiths, Graham Bothamley, Onn Min Kon, Andrew Hayward, Joanne Lord, Francis Drobniewski. Two interferon gamma release assays for predicting active tuberculosis: the UK PREDICT TB prognostic test study. Health Technology Assessment 2018; 22(56): 1 doi: 10.3310/hta22560
|
| 8 |
Jae Hee Cheon. Understanding the complications of anti‐tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease. Journal of Gastroenterology and Hepatology 2017; 32(4): 769 doi: 10.1111/jgh.13612
|
| 9 |
V.B. Pereira, V.P. da Cunha, T.M. Preisser, B.M. Souza, M.Z. Turk, C.P. De Castro, M.S.P. Azevedo, A. Miyoshi. Lactococcus lactiscarrying a DNA vaccine coding for theESAT-6antigen increases IL-17 cytokine secretion and boosts the BCG vaccine immune response. Journal of Applied Microbiology 2017; 122(6): 1657 doi: 10.1111/jam.13449
|
| 10 |
Saurabh Kedia, Venigalla Pratap Mouli, Nagesh Kamat, Jeeva Sankar, Ashwin Ananthakrishnan, Govind Makharia, Vineet Ahuja. Risk of Tuberculosis in Patients With Inflammatory Bowel Disease on Infliximab or Adalimumab Is Dependent on the Local Disease Burden of Tuberculosis: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology 2020; 115(3): 340 doi: 10.14309/ajg.0000000000000527
|
| 11 |
Dong II Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin‐Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasuo Suzuki, Kentaro Sugano, Mamoru Watanabe, Toshifumi Hibi, Amarender S Puri, Suk‐Kyun Yang. Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti‐tumor necrosis factor treatment. Part 1: Risk assessment. Journal of Gastroenterology and Hepatology 2018; 33(1): 20 doi: 10.1111/jgh.14019
|
| 12 |
Maede Ghanaeipour, Nima Behnaminia, Erfan Khadem, Amirhossein Nafari. The Risk of Opportunistic Infections in Patients with Inflammatory
Bowel Disease. The International Journal of Gastroenterology and Hepatology Diseases 2022; 1(1) doi: 10.2174/2666290601666220124111511
|
| 13 |
Arisa Iba, Jun Tomio, Hayato Yamana, Takehiro Sugiyama, Takashi Yoshiyama, Yasuki Kobayashi. Tuberculosis screening and management of latent tuberculosis infection prior to biologic treatment in patients with immune‐mediated inflammatory diseases: A longitudinal population‐based analysis using claims data. Health Science Reports 2020; 3(4) doi: 10.1002/hsr2.216
|
| 14 |
Hsiang-Chun Lai, Chia-Hsi Chang, Ken-Sheng Cheng, Tsung-Wei Chen, Yuan-Yao Tsai, Jen-Wei Chou. QuantiFERON-TB Gold Test Conversion Is Associated with Active Tuberculosis Development in Inflammatory Bowel Disease Patients Treated with Biological Agents: An Experience of a Medical Center in Taiwan. Gastroenterology Research and Practice 2019; 2019: 1 doi: 10.1155/2019/7132875
|
| 15 |
Jungsil Lee, Eunyoung Kim, Eun Jin Jang, Chang-Hoon Lee, Eun Young Lee, Jong Pil Im, Sung Koo Han, Jae-Joon Yim. Efficacy of Treatment for Latent Tuberculosis in Patients Undergoing Treatment with a Tumor Necrosis Factor Antagonist. Annals of the American Thoracic Society 2017; 14(5): 690 doi: 10.1513/AnnalsATS.201608-647OC
|
| 16 |
S. N. Hong, H. J. Kim, K. H. Kim, S.‐J. Han, I. M. Ahn, H. S. Ahn. Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease: a nationwide population‐based study in South Korea. Alimentary Pharmacology & Therapeutics 2017; 45(2): 253 doi: 10.1111/apt.13851
|
| 17 |
Diana Castillo-Martínez, Luis M. Amezcua-Castillo, Julio Granados, Carlos Pineda, Luis M. Amezcua-Guerra. Is Takayasu arteritis the result of a Mycobacterium tuberculosis infection? The use of TNF inhibitors may be the proof-of-concept to demonstrate that this association is epiphenomenal. Clinical Rheumatology 2020; 39(6): 2003 doi: 10.1007/s10067-020-05045-z
|
| 18 |
Anna Shin, Yun Jong Lee, Eun Bong Lee, Yeong Wook Song, Seoyoung C Kim, Eun Ha Kang. Tuberculosis risk with biologics by screening-guided preventive strategy in rheumatoid arthritis under intermediate tuberculosis burden. Rheumatology 2021; 60(6): 2755 doi: 10.1093/rheumatology/keaa702
|
| 19 |
Ying Zhou, Chun-yan Tan, Zhi-jiang Mo, Qi-le Gao, Dan He, Jiong Li, Rong-fu Huang, Yan-bing Li, Chao-feng Guo, Qiang Guo, Long-jie Wang, Guan-teng Yang, Hong-qi Zhang. Polymorphisms in theSP110andTNF-αGene and Susceptibility to Pulmonary and Spinal Tuberculosis among Southern Chinese Population. Disease Markers 2017; 2017: 1 doi: 10.1155/2017/4590235
|
| 20 |
Peeyush Kumar, Sudheer K. Vuyyuru, Bhaskar Kante, Pabitra Sahu, Sandeep Goyal, Deepak Madhu, Saransh Jain, Mukesh Kumar Ranjan, Sandeep Mundhra, Rithvik Golla, Mukesh Singh, Shubi Virmani, Anvita Gupta, Nidhi Yadav, Mani Kalaivani, Raju Sharma, Prasenjit Das, Govind Makharia, Saurabh Kedia, Vineet Ahuja. Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti‐TNF therapy in tuberculosis endemic region. Alimentary Pharmacology & Therapeutics 2022; 55(11): 1431 doi: 10.1111/apt.16839
|
| 21 |
Roger M. Feakins. Non-Neoplastic Pathology of the Gastrointestinal Tract. 2020; doi: 10.1017/9781316823026
|
| 22 |
Ashish Agarwal, Saurabh Kedia, Saransh Jain, Vipin Gupta, Sawan Bopanna, Dawesh P Yadav, Sandeep Goyal, Venigalla Pratap Mouli, Rajan Dhingra, Govind Makharia, Vineet Ahuja. High risk of tuberculosis during infliximab therapy despite tuberculosis screening in inflammatory bowel disease patients in India. Intestinal Research 2018; 16(4): 588 doi: 10.5217/ir.2018.00023
|
| 23 |
Yue Yu, Qiao Yu, Ke Ren Shen, Ding Ting Xu, Wen Hu, Shu Yan Li, Qing Shan Cai, Yan Chen. New‐onset extrapulmonary tuberculosis in negative latent tuberculosis infection screening patients with Crohn's disease under anti‐TNF therapy in a tuberculosis‐endemic region: A case series. Journal of Digestive Diseases 2023; 24(5): 369 doi: 10.1111/1751-2980.13206
|
| 24 |
Jason K. Hou, Jennifer R. Kramer, Peter Richardson, Shubhada Sansgiry, Hashem B. El-Serag. Tuberculosis Screening and Reactivation Among a National Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Alpha Antagonists. Inflammatory Bowel Diseases 2017; 23(2): 254 doi: 10.1097/MIB.0000000000001003
|
| 25 |
Jae Yong Lee, Kyunghwan Oh, Hee Seung Hong, Kyuwon Kim, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Ho-Su Lee, Kyung-Wook Jo, Sang Hyoung Park. Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea. BMC Gastroenterology 2021; 21(1) doi: 10.1186/s12876-021-01973-5
|
| 26 |
Jun Tomio, Hayato Yamana, Hiroki Matsui, Hiroyuki Yamashita, Takashi Yoshiyama, Hideo Yasunaga. Tuberculosis screening prior to anti‐tumor necrosis factor therapy among patients with immune‐mediated inflammatory diseases in Japan: a longitudinal study using a large‐scale health insurance claims database. International Journal of Rheumatic Diseases 2017; 20(11): 1674 doi: 10.1111/1756-185X.13190
|
| 27 |
Aye Aye Thi, Aula Abbara, Sonia Bouri, Simon M Collin, Paul Wolfson, Leah Owen, Kevin G Buell, Laurence John, Ailsa L Hart. Challenges in screening for latent tuberculosis in inflammatory bowel disease prior to biologic treatment: a UK cohort study. Frontline Gastroenterology 2018; 9(3): 234 doi: 10.1136/flgastro-2017-100951
|
| 28 |
Michael Kwan‐Lung Ko, Siew C Ng, Lung‐Yi Mak, Michael K Li, Fu Hang Lo, Carmen Ka Man Ng, Wai Cheung Lao, Steve Tsang, Kam Hon Chan, Yee Tak Hui, Edwin Hok Shing Shan, Ching Kong Loo, Aric J Hui, Wai Pan To, Ivan F Hung, Wai K Leung. Infection‐related hospitalizations in the first year after inflammatory bowel disease diagnosis. Journal of Digestive Diseases 2016; 17(9): 610 doi: 10.1111/1751-2980.12397
|
| 29 |
Jang Wook Lee, Chang Hwan Choi, Ji Hoon Park, Jeong Wook Kim, Sang Bum Kang, Ja Seol Koo, Young-Ho Kim, You Sun Kim, Young Eun Joo, Sae Kyung Chang. Clinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease. Intestinal Research 2016; 14(2): 146 doi: 10.5217/ir.2016.14.2.146
|
| 30 |
Hyeonseok Noh, Jeongju Jang, Seungwon Kwon, Seung-Yeon Cho, Woo-Sang Jung, Sang-Kwan Moon, Jung-Mi Park, Chang-Nam Ko, Ho Kim, Seong-Uk Park. The Impact of Korean Medicine Treatment on the Incidence of Parkinson’s Disease in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study in South Korea. Journal of Clinical Medicine 2020; 9(8): 2422 doi: 10.3390/jcm9082422
|
| 31 |
Guilherme P Ramos, Gregory Stroh, Badr Al-Bawardy, William A Faubion, Konstantinos A Papadakis, Patricio Escalante. Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy. Inflammatory Bowel Diseases 2018; 24(10): 2272 doi: 10.1093/ibd/izy133
|
| 32 |
Flora Maria Lorenzo Fortes, Ney Boa Sorte, Victor D Mariano, Laíla D Andrade, Fernanda A Oliveira, Monique CA Santos, Cláudia Ivanilda N dos Santos, Catharina A Passos, Mila P Pacheco, Valdiana C Surlo, Neogélia P de Almeida, Jaciane AM Fontes, Andréa M Pimentel, Raquel Rocha, Genoile Oliveira Santana. Active tuberculosis in inflammatory bowel disease patients under treatment from an endemic area in Latin America. World Journal of Gastroenterology 2020; 26(44): 6993-7004 doi: 10.3748/wjg.v26.i44.6993
|
| 33 |
Roger M Feakins. Morson and Dawson's Gastrointestinal Pathology. 2024; : 709 doi: 10.1002/9781119423195.ch35
|
| 34 |
Suprabhat Giri, Sukanya Bhrugumalla, Akash Shukla, Sagar Gangadhar, Srujan Reddy, Sumaswi Angadi, Leela Shinde, Aditya Kale. Risk of tuberculosis with anti-TNF therapy in Indian patients with inflammatory bowel disease despite negative screening. Arab Journal of Gastroenterology 2024; doi: 10.1016/j.ajg.2024.01.013
|